- Population-based study of BRCA1/2 mutations: family history based criteria identify minority of mutation carriers.2010 | First Faculty of Medicine
- Effect of cytostatics on primary mammary cells with hederitary mutation in gene BRCA1/2Publication without faculty affiliation
- Nové možnosti léčby pacientek s mutacemi genů BRCA1/2 a karcinomem ovarií2017 | First Faculty of Medicine
- Satisfaction and overall quality of life in BRCA positive women after prophylactic surgeries2017 | First Faculty of Medicine
- Gynekologická prevence a aspekty gynekologické péče u nosiček mutací genů BRCA1/22022 | First Faculty of Medicine
- Molecular biology testing in breast cancer2020 | First Faculty of Medicine
- Inactivation of BRCA1/2, TP53 and ATM genes in sporadic breast tumorsPublication without faculty affiliation
- Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers2022 | First Faculty of Medicine
- BRCA mutation carriers suffering from ovarian cancer as a model for treatment decision in higher lines - Place for platinum reinduction2023 | First Faculty of Medicine, Third Faculty of Medicine
- Risk Factors in Ovarian Cancer: A Brief Overview2015 | First Faculty of Medicine, Central Library of Charles University
- CIM Brca1 2 AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A consortium of investigators of modifiers of BRCA1/2 study2007 | First Faculty of Medicine
- CIM Brca1 2 AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A consortium of investigators of modifiers of BRCA1/2 study2007 | Faculty of Physical Education and Sport
- Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial2020 | First Faculty of Medicine
- BRCA1 and BRCA2 - pathologist's starting kit2016 | Second Faculty of Medicine
- olaparib2017 | First Faculty of Medicine
- European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancerPublication without faculty affiliation
- Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum2016 | First Faculty of Medicine, Second Faculty of Medicine
- Testing of mutations in BRCA1 and BECA2 genes in tumor tissues - possibilities and limitations2016 | Faculty of Medicine in Hradec Králové
- Udržovací léčba niraparibem u pacientky s karcinomem vaječníků2023 | First Faculty of Medicine
- Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene2010 | First Faculty of Medicine
- Analysis of BRCA1 and BRCA2 mutations in high-risk patients from the Prague areaPublication without faculty affiliation
- Inactivation of tumor supressor genes BRCA1, BRCA2 and p53 in epithelial ovarian tumorsPublication without faculty affiliation
- Niraparib2021 | First Faculty of Medicine
- Overview on population screening for carriers with germline BRCA mutation in China2022 | Faculty of Medicine in Pilsen
- Uptake and Effectiveness of Risk-Reducing Surgeries in Unaffected Female BRCA1 and BRCA2 Carriers: A Single Institution Experience in the Czech Republic2023 | First Faculty of Medicine
- Recommendations for follow-up of cancer patients and healthy carriers with BRCA1 or BRCA2 mutations2003 | First Faculty of Medicine
- Recommendations for follow-up of cancer patients and healthy carriers with BRCA1 or BRCA2 mutations2003 | Faculty of Physical Education and Sport
- High frequency of BRCA 1/2 and p53 somatic inactivation in sporadic ovarian cancer2007 | First Faculty of Medicine
- The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development2011 | First Faculty of Medicine
- Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.2011 | First Faculty of Medicine